Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis (P12-4.002)

Yves Dauvilliers; Emmanuel Mignot; Giuseppe Plazzi; Gert Jan Lammers; Harisha Kadali; Ellie Stukalin; Yaming Hang; Yeting Du; Anson Abraham; Philipp von Rosenstiel; Shinichiro Tanaka; Melissa Naylor; Alice Cai; Tina Olsson

doi:10.1212/WNL.0000000000208433

Retour

Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis (P12-4.002)

Article de revue

Avec comité de lecture

Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis (P12-4.002)

Yves Dauvilliers, Emmanuel Mignot, Giuseppe Plazzi, Gert Jan Lammers, Harisha Kadali, Ellie Stukalin, Yaming Hang, Yeting Du, Anson Abraham, Philipp von Rosenstiel, …

Neurology, Vol.104(7_Supplement_1)

08/04/2025

DOI: https://doi.org/10.1212/WNL.0000000000208433

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

Détails

Titre: Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis (P12-4.002)
Créateurs - sans rôle: Yves Dauvilliers
Emmanuel Mignot
Giuseppe Plazzi
Gert Jan Lammers
Harisha Kadali
Ellie Stukalin
Yaming Hang
Yeting Du
Anson Abraham
Philipp von Rosenstiel
Shinichiro Tanaka
Melissa Naylor
Alice Cai
Tina Olsson
Détails de publication: Neurology, Vol.104(7_Supplement_1)
Identifiants: 99140212509311
Unité académique: Institut des Neurosciences de Montpellier - INM
Langue: English
Type de ressource: Journal article